KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Equity Average (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Equity Average data on record, last reported at $710.2 million in Q4 2025.

  • For Q4 2025, Equity Average fell 7.04% year-over-year to $710.2 million; the TTM value through Dec 2025 reached $710.2 million, down 7.04%, while the annual FY2025 figure was $735.7 million, 10.74% down from the prior year.
  • Equity Average reached $710.2 million in Q4 2025 per PCRX's latest filing, down from $742.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $885.7 million in Q2 2024 and bottomed at $635.3 million in Q1 2021.
  • Average Equity Average over 5 years is $765.8 million, with a median of $767.7 million recorded in 2023.
  • Peak YoY movement for Equity Average: soared 75.55% in 2021, then fell 12.14% in 2025.
  • A 5-year view of Equity Average shows it stood at $724.5 million in 2021, then increased by 6.63% to $772.6 million in 2022, then increased by 10.13% to $850.8 million in 2023, then decreased by 10.21% to $764.0 million in 2024, then dropped by 7.04% to $710.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $710.2 million in Q4 2025, $742.5 million in Q3 2025, and $778.2 million in Q2 2025.